Estimated cardiovascular relative risk reduction from fixed-dose combination pill (polypill) treatment in a wide range of patients with a moderate risk of cardiovascular disease

European Journal of Preventive Cardiology

Volumn 23, Issue 12, 2016, Pages 1289-1297

  Lafeber, Melvin ^a,b   Webster, Ruth ^c   Visseren, Frank L J ^b   Bots, Michiel L ^a   Grobbee, Diederick E ^a,c   Spiering, W ^b   Rodgers, Anthony ^c  

^a Julius Center for Health Sciences and Primary Care   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c UNIVERSITY OF SYDNEY   (Australia)

Author keywords

aspirin; blood pressure lowering drugs; Polypill; prevention; statin

Indexed keywords

ACETYLSALICYLIC ACID; HYDROCHLOROTHIAZIDE; LISINOPRIL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; SIMVASTATIN; CARDIOVASCULAR AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; COUGHING; DIZZINESS; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PILL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; STOMACH IRRITATION; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; CLINICAL TRIAL; DOSE RESPONSE; DRUG COMBINATION; GLOBAL HEALTH; MEDICATION COMPLIANCE; MIDDLE AGED; MORBIDITY; PROCEDURES; RISK ASSESSMENT; RISK FACTOR; TIME FACTOR; TRENDS;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; DIURETICS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; FEMALE; FOLLOW-UP STUDIES; GLOBAL HEALTH; HUMANS; HYDROCHLOROTHIAZIDE; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LISINOPRIL; MALE; MEDICATION ADHERENCE; MIDDLE AGED; MORBIDITY; RISK ASSESSMENT; RISK FACTORS; SIMVASTATIN; TIME FACTORS; TREATMENT OUTCOME;

EID: 84979021808     PISSN: 20474873     EISSN: 20474881     Source Type: Journal    
DOI: 10.1177/2047487315624523     Document Type: Article

References (22)

1. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2095-2128.
2. Jackson R, Barham P, Bills J, et al. Management of raised blood pressure in New Zealand: A discussion document. Br Med J 1993; 307: 107-110.
3. Diabetes UK, et al. British Cardiac Society, British Hypertension Society. JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart 2005; 91: v1-v52.
4. National Vascular Disease Prevention Alliance (NVDPA). Guidelines for the management of absolute cardiovascular disease risk, Canberra, Australia: National Heart Foundation of Australia, 2012.
5. Browne JL, Grobbee DE,. Cardiovascular prevention and international health: Time for action. Eur J Prev Cardiol 2011; 18: 547-549.
6. Lafeber M, Spiering W, Singh K, et al. The cardiovascular polypill in high-risk patients. Eur J Cardiovasc Prev Rehabil 2012; 19: 1234-1242.
7. Elley CR, Gupta AK, Webster R, et al. The efficacy and tolerability of 'polypills': Meta-analysis of randomised controlled trials. PLoS One 2012; 7: e52145-e52145.
8. Rodgers A, Patel A, Berwanger O, et al. An international randomised placebo-controlled trial of a four-component combination pill ("polypill") in people with raised cardiovascular risk. PLoS One 2011; 6: e19857-e19857.
9. Thom S, Field J, Poulter N, et al. Use of a multidrug pill in reducing cardiovascular events (UMPIRE): Rationale and design of a randomised controlled trial of a cardiovascular preventive polypill-based strategy in India and Europe. Eur J Prev Cardiol 2014; 21: 252-261.
10. Patel A, Cass A, Peiris D, Kanyini Guidelines adherence with the polypill collaboration,. A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk. Eur J Prev Cardiol 2015; 22: 920-930.
11. Law MR, Wald NJ,. Risk factor thresholds: Their existence under scrutiny. Br Med J 2002; 324: 1570-1576.
12. Anderson KM, Wilson PW, Odell PM, et al. An updated coronary risk profile. A statement for health professionals. Circulation 1991; 83: 356-362.
13. Riddell T, Wells S, Jackson R, et al. Performance of Framingham cardiovascular risk scores by ethnic groups in New Zealand: PREDICT CVD-10. N Z Med J 2010; 123: 50-61.
14. Baigent C, Blackwell L, et al. Antithrombotic Trialists Collaboration. Aspirin in the primary and secondary prevention of vascular disease: Collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373: 1849-1860.
15. Law MR, Wald NJ, Rudnicka AR,. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: Systematic review and meta-analysis. Br Med J 2003; 326: 1423-1430.
16. Law MR, Morris JK, Wald NJ,. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: Meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. Br Med J 2009; 338: b1665-b1665.
17. Mihaylova B, Emberson J, Blackwell L, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: Meta-analysis of individual data from 27 randomised trials. Lancet 2012; 380: 581-590.
18. Alderman MH,. Blood pressure management: Individualized treatment based on absolute risk and the potential for benefit. Ann Intern Med 1993; 119: 329-335.
19. Jackson R, Lawes CM, Bennett DA, et al. Treatment with drugs to lower blood pressure and blood cholesterol based on an individual's absolute cardiovascular risk. Lancet 2005; 365: 434-441.
20. Shepherd J,. Resource management in prevention of coronary heart disease: Optimising prescription of lipid-lowering drugs. Lancet 2002; 359: 2271-2273.
21. Smith MEB, Lee NJ, Haney E, et al. Drug class review: HMG-CoA reductase inhibitors (statins) and fixed-dose combination products containing a statin: Final report Update 5. 2010/12/07 ed. Portland, OR: Oregon Health and Science University, 2009.
22. Dicpinigaitis PV,. Angiotensin-converting enzyme inhibitor-induced cough: ACCP evidence-based clinical practice guidelines. Chest 2006; 129: 169S-173S.